Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 41.28 USD 0.98% Market Closed
Market Cap: 11.1B USD

Intrinsic Value

The intrinsic value of one EXEL stock under the Base Case scenario is 47.98 USD. Compared to the current market price of 41.28 USD, Exelixis Inc is Undervalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EXEL Intrinsic Value
47.98 USD
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Exelixis Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about EXEL?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is EXEL valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Exelixis Inc.

Explain Valuation
Compare EXEL to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Exelixis remains heavily reliant on cabozantinib-based therapies for revenue, exposing it to significant downside risk if competition or unfavorable trial data diminishes demand for this cornerstone product.

The company’s pipeline diversification efforts beyond cabozantinib have yet to demonstrate substantial commercial viability, raising concerns about the long-term sustainability of its R&D strategy.

Exelixis faces increasing patent and pricing pressures, as competitors target the same oncology segments with novel therapies, potentially undermining the firm’s margins and market share.

Bull Theses

Cabometyx has shown strong clinical performance in multiple indications, and its success in kidney and liver cancers could lead to expanded use cases and sustained revenue growth.

Exelixis has historically maintained strategic partnerships with larger pharmaceutical companies, which helps reduce commercialization costs and expand global reach for its lead products.

A growing cash position and disciplined approach to R&D spending have provided Exelixis with the flexibility to pursue new drug candidates without significantly endangering its balance sheet.

Show More Less
How do you feel about EXEL?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Exelixis Inc

Current Assets 1.4B
Cash & Short-Term Investments 988.5m
Receivables 309.7m
Other Current Assets 104m
Non-Current Assets 1.4B
Long-Term Investments 578.3m
PP&E 104.7m
Intangibles 63.7m
Other Non-Current Assets 674.6m
Current Liabilities 373.8m
Accounts Payable 25.3m
Accrued Liabilities 185.6m
Other Current Liabilities 162.9m
Non-Current Liabilities 289.1m
Other Non-Current Liabilities 289.1m
Efficiency

Free Cash Flow Analysis
Exelixis Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Exelixis Inc

Revenue
2.3B USD
Cost of Revenue
-77.2m USD
Gross Profit
2.2B USD
Operating Expenses
-1.4B USD
Operating Income
820.3m USD
Other Expenses
-142.3m USD
Net Income
677.9m USD
Fundamental Scores

EXEL Profitability Score
Profitability Due Diligence

Exelixis Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Exceptional ROIC
Exceptional ROE
Exceptional Gross Margin
Exceptional Operating Margin
69/100
Profitability
Score

Exelixis Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

EXEL Solvency Score
Solvency Due Diligence

Exelixis Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
80/100
Solvency
Score

Exelixis Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EXEL Price Targets Summary
Exelixis Inc

Wall Street analysts forecast EXEL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXEL is 45.9 USD with a low forecast of 30.3 USD and a high forecast of 63 USD.

Lowest
Price Target
30.3 USD
27% Downside
Average
Price Target
45.9 USD
11% Upside
Highest
Price Target
63 USD
53% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Exelixis Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for EXEL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

EXEL Insider Trading
Buy and sell transactions by insiders

EXEL News

Other Videos
What is the Intrinsic Value of one EXEL stock?

The intrinsic value of one EXEL stock under the Base Case scenario is 47.98 USD.

Is EXEL stock undervalued or overvalued?

Compared to the current market price of 41.28 USD, Exelixis Inc is Undervalued by 14%.

Back to Top